Synthis is a NYC-based biotech company developing a first in class, therapeutic platform that restores immune function and tumor clearance in checkpoint resistant cancer patients. While immune checkpoint inhibitors are 1st line treatment for many cancers, <30% of all patients actually respond. Our platform selectively eliminates one of the most immune-suppressive pathways in all solid tumors, known as TGF-b. TGF-b also drives resistance to checkpoint therapies. To address the significant need for novel combination therapies, we are developing targeted TGF-b inhibitors that combine with checkpoint therapies to boost response patient response rates in cancers such as colon, skin and liver.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):